ZOSOBACT-1.5 Injection

ZOSOBACT-1.5gm Injection an advanced dual-power antibiotic injection designed to provide rapid and effective eradication of severe infections while ensuring maximum safety. Formulated with Cefoperazone and Sulbactam, it delivers broad-spectrum coverage against resistant bacteria. Clinically proven to achieve high success rates in treating urinary tract infections, intra-abdominal infections, bone and joint infections, and skin and soft tissue infections. Trusted for its superior efficacy and reduced adverse effects, making it an ideal choice for healthcare professionals aiming for optimal patient outcomes.

Category: Anti-Infective

Description

Description

Product Description:

ZOSOBACT-1.5 is a potent combination of Cefoperazone (1 gm) and Sulbactam (500 mg) that works synergistically to treat a wide range of bacterial infections. This powerful formulation offers no compromise on treatment efficacy, especially in critical cases of UTI, intra-abdominal infections, bone & joint infections, and SSTI.

The inclusion of Sulbactam enhances the spectrum of Cefoperazone by inhibiting beta-lactamase enzymes, thus providing extended and reliable coverage against resistant strains. It’s widely preferred in hospital setups for its 100% UTI eradication rate and 91.9% clinical success rate in intra-abdominal infections (IAI).

With a proven safety profile and reduced adverse effects, ZOSOBACT-1.5 is a trusted solution for physicians who demand consistent results without compromise.

Key Features:

100% eradication rate in UTI
91.9% clinical success in intra-abdominal infections
Enhanced spectrum with dual action
Safer treatment with minimal adverse effects
Ideal for critical care and post-operative infections

Indications:

ZOSOBACT-1.5 is indicated in the treatment of:

Urinary Tract Infections (UTI)
Intra-abdominal infections
Bone and Joint infections
Skin and Soft Tissue Infections (SSTI)

Dosage & Administration:

For I.M./I.V. use only
To be administered under the supervision of a registered medical practitioner. Dosage should be determined by the severity and type of infection.